Pharmacokinetics of a new fixed-dose combination of candesartan cilexetil, hydrochlorothiazide, and...
Pharmacokinetics of a new fixed-dose combination of candesartan cilexetil, hydrochlorothiazide, and rosuvastatin in healthy adult subjects
About this item
Full title
Author / Creator
Publisher
Germany: Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG
Journal title
Language
English
Formats
Publication information
Publisher
Germany: Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG
Subjects
More information
Scope and Contents
Contents
A fixed-dose combination (FDC) of candesartan cilexetil, hydrochlorothiazide and rosuvastatin (CC/HCTZ/RSV) has been developed to enhance patient compliance in the primary prevention of cardiovascular diseases.
To evaluate if the combination of the product components in the new FDC capsule formulation affects their respective pharmacokinetic and...
Alternative Titles
Full title
Pharmacokinetics of a new fixed-dose combination of candesartan cilexetil, hydrochlorothiazide, and rosuvastatin in healthy adult subjects
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2624654617
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2624654617
Other Identifiers
ISSN
0946-1965
DOI
10.5414/CP204026
